PROTECT interim results: a large multicenter study of patients with type II diabetes

Clissold, 1988, Acarbose: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential, Drugs, 35, 214, 10.2165/00003495-198835030-00003 Muller, 1986, Acarbose (Bay g 5421) kinetics in healthy volunteers, Acta Pharmacol Toxicol, 59, 303 Putter, 1982, Pharmacokinetics of acarbose, 38 Hagel, 1985, α-Glucosidase inhibitor acarbose: Fate and effects in man, Gastroenterology, 88, 1410 Radziuk, 1982, Quantitation of the effects of the α-glucosidase inhibitor acarbose on the hydrolysis and absorption of sucrose and hormone responses in man, 113 Buber, 1982, Effect of acarbose in non-insulin dependent diabetic patients during long-term treatment, 266 Orimo, 1982, Usefulness of acarbose in the management of non-insulin dependent diabetes in the aged, 348 Coniff, 1995, Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM, Diabetes Care, 18, 817, 10.2337/diacare.18.6.817 1987, Assessment of hemoglobin A1c in the Diabetes Control and Complications Trial (DCCT), Clin Chem, 33, 2267 Gault, 1992, Predicting glomerular function from adjusted serum creatinine, Nephron, 62, 249, 10.1159/000187054 Coniff, 1994, Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin dependent diabetes mellitus, Arch Intern Med, 154, 2442, 10.1001/archinte.154.21.2442 1993, The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, NEJM, 329, 977, 10.1056/NEJM199309303291401